Trials Sponsors Conditions Drugs Pricing

Conditions

End Stage Renal Disease

Keywords

Middle Molecules clearance in HDFHDFMiddle moleculesbeta 2 microglobulinHDF convection volume

Outcome Measures

Primary Outcomes (2)

The relationship between HDF convection volume and β2 Microglobulin reduction ratio during a HDF session.
18 months
The relationship between HDF convection volume and serum pre dialysis β2 Microglobulin concentration (measured in mg/L).
18 months

Secondary Outcomes (3)

The relationship of HDF convection volume with average intradialytic blood pressure (mmHg).
18 months
The relationship of HDF convection volume with average intradialytic core body temperature (degrees centigrade)
18 months
The relationship of HDF convection volume with CRP (mg/L).
18 months

Study Arms (1)

HDF patients

ESRF patients who are receiving renal replacement therapy in the form of HDF

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

End stage renal failure patient having renal replacement therapy in the form of Haemodiafiltration.

You may qualify if:

Age 18 years or above.

Sponsors & Collaborators

East and North Hertfordshire NHS Trust
Governmentlead

Study Sites (1)

East and North Hertfordshire NHS Trust

Stevenage, Hertfordshire, SG1 4AB, United Kingdom

MeSH Terms

Conditions

Kidney Failure, Chronic

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

Usama A Butt, MBBS, MRCP
East and North Hertfordshire NHS Trust
PRINCIPAL INVESTIGATOR

Enrollment

342 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER GOV
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 16, 2024

First Posted

July 23, 2024

Study Start

January 19, 2024

Actual (reported)

Association of Middle Molecules Clearance With HDF Volume

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Study Arms (1)

HDF patients

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (2)

Secondary Outcomes (3)

Study Arms (1)

HDF patients

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations